USP9X and myelodysplastic syndrome: To test the possibility that USP9X, RBBP6, ZBTB38, and/or CDKN1C could be predictive markers, we retrieved the clinical and gene expression data from a previously published cohort of patients with MDS showing effective and tolerable effects of 5-azacytidine1.